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Little is known about collagen XI expression in normal and malignant breast tissue. Tissue microarrays,
constructed from 72 patients with breast carcinoma and matched normal tissue, were immunohistochemically
stained with five antisera against isoform-specific regions of collagen a1(XI) N-terminal domain. Staining
intensity was graded on a 0–3 scale in epithelial cytoplasm, stroma, and endothelial staining of the vasculature
of each tissue core. The staining was compared to known pathologic parameters: age, tumor size, overall tumor
grade, nuclear grade, tubule formation, mitotic counts, angiolymphatic invasion, node status, estrogen receptor
status, progesterone receptor status, and HER-2/neu status. Estrogen and progesterone receptor status were
used as a control for comparison. With antisera V1a and amino propeptide (Npp), stroma surrounding
cancerous cells was found to have decreased collagen a1(XI) staining compared to stroma adjacent to normal
epithelium (P¼ 0.0006, Po0.0001). Collagen a1(XI) staining with V1a antiserum in cytoplasm of cancer cells
demonstrated decreased intensity in metastasized primary tumors when compared to nonmetastasized primary
tumors (P¼ 0.009). Cytoplasmic staining with Npp antiserum in cancer demonstrated an inverse relationship to
positive estrogen receptor status in cancer (P¼ 0.012) and to progesterone receptor status (P¼ 0.044). Stromal
staining for Npp in cancerous tissue demonstrated an inverse relationship with tubule formation score
(P¼ 0.015). This is the first study to localize collagen XI within normal and malignant breast tissue. Collagen
a1(XI) appears to be downregulated in stroma surrounding breast cancer. Detection of collagen XI in breast
tissue may help predict women who have lymph node metastases.
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Approximately 180 000 US women will be diag-
nosed with breast cancer in the year 2007.1 Sentinel
lymph node biopsy has become the favored method
for the nodal staging of breast cancer. Looking for
alternatives to invasive procedures such as sentinel
lymph node biopsy is imperative for improving
patient care. Known predictors of metastasis have
been studied extensively: age, race, menopausal
status, palpability, tumor size, positive margin on
initial excision, histopathologic diagnosis, tumor
grade, mitotic counts, nuclear polymorphism, tubule
formation as an indication of tumor differentiation,
lymphatic and vascular invasion, estrogen receptor
status, progesterone receptor status, and HER-2/neu
status.2–8
Collagen XI, a minor collagen found in many
tissues, but characterized most thoroughly in carti-
lage, nucleates, and regulates formation of thin
fibrils of developing or remodeling tissues.9–13 It is a
heterotrimeric protein, consisting of three a-chains
organized into a triple helix. Both a1(XI) and a2(XI)
are unique gene products, and a3(XI) is a hypergly-
colsylated version of the collagen (a1)II chain.14,15
Originally synthesized as procollagen, collagen XI has
its C and N termini proteolytically removed after
secretion from the cell.16,17 An N-terminal domain
(NTD), consisting of a variable region and an amino
propeptide (Npp) exists in a1(XI) and a2(XI). Alter-
native splicing of three separate exons (6a, 6b, and 8)
may produce eight unique spliceforms encoding the
corresponding protein regions p6a (V1a), p6b (V1b),
and p8 (V2; Figure 1).18,19 Common to all spliceforms
are the Npp encoded by exons 2–5, and the C2 region,
encoded by exon 7 (Figure 1 and Table 1).
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While the major triple helix of collagens may be
difficult to access in immunohistochemical proce-
dures, the NTD may be a more useful target.
Previous studies have demonstrated the surface
location and its persistence following biosynth-
esis.20,21
It has been found that several genes encoding
extracellular matrix components including COL6A3
and COL8A1 were upregulated in cancer cells when
compared with normal tissue.22 A previous study
evaluated the expression of the gene COLXIA1
coding collagen a1(XI) between primary cancer
and paired lymph node metastases as a predictor
of clinical outcome of node-positive breast cancer
patients. It was found that there was decreased
expression of COLXIA1 in lymph node metastatic
tissue as confirmed by reverse transcription (RT)–
PCR.23 Finally, downregulation of all collagen has
been shown in breast cancer tissue when compared
with normal tissue.24 Modification in cancerous
breast tissue collagen metabolism may reflect tissue
remodeling, which is typical for the invasive
phenotype of malignant cells.24
Collagen is known to play an active role in
numerous biological processes such as cell morpho-
genesis, proliferation, migration, differentiation,
apoptosis as well as carcinogenesis. Upregulation
of collagen in carcinomas has been demonstrated in
a variety of organs including colorectal tumors, non-
small-cell lung cancer, and high-grade prostate
carcinoma.25–28 It was found that colon mucosal
stroma in the majority of colorectal cancers ex-
pressed COLXIA1, whereas it was rarely expressed
in normal colon mucosa.25 In a study involving
non-small-cell lung cancer, collagen a1(XI) was
overexpressed at high frequency among both ade-
nocarcinoma and squamous cell carcinoma.29 This
study aims to analyze the presence of collagen
a1(XI) spliceforms in normal and malignant human
breast tissue while also evaluating the relationships
to clinical/pathologic parameters including its
ability to predict lymph node metastases.
Materials and methods
Five antisera were raised against specific portions of
the collagen a1(XI) molecule. A purified 40-amino-
acid (AA) synthetic peptide was used to generate a
polyclonal antiserum to V1a (exon 6a) that has the
potential to recognize spliceforms Col11a1p6a,
Col11a1p6a78, Col11a1p6a6b, and Col11a1p6a6b78.
A 29-AA synthetic peptide was used to generate a
polyclonal antiserum that has the capacity to
recognize all possible spliceforms through interac-
tion with the epitope in the constitutively expressed
exon 7 region (referred to as C2). An 11-AA
synthetic peptide designed from the C terminus of
the cleaved Npp was used to generate a polyclonal
antiserum to a1(XI) Npp that has the capacity to
recognize all possible spliceforms.20,30,31 A 20-AA
synthetic peptide designed from the carboxy portion
of V2 was used to generate a polyclonal antiserum to
a1(XI) V2 (exon p8) that has the potential to
recognize spliceforms Col1a1p8, Col11a1p6a78, Co-
l11a1p6b78, and Col11a1p6a6b78. A purified 51-AA
rat recombinant was used to generate a monoclonal
antibody to V1b (exon p6b) that has the potential to
recognize spliceforms Col11a1p6b, Col11a1p6a6b,
Col11a1p6b78, and Col11a1p6a6b78 (Figure 1 and
Table 1). The antibody specificity has been formerly
characterized for rat, mouse, bovine, and human
tissues.19,20,32 RT–PCR was performed to confirm
Figure 1 Schematic illustration of collagen a1(XI) N-terminal
domain. Positions of target sequences are labeled for each of the
antisera used in this study. The V1a region is recognized by
antiserum V1a, the C2 region is recognized by antiserum C2, and
the Npp is recognized by antiserum Npp. Col11a1 fragment was
amplified by RT–PCR. (Lane 1) PCR control with no reverse
transcriptase added; (lane 2) mRNA isolated from human
mammary epithelial cells (HMEC), amplified with primers
specific for the housekeeping gene GAPDH; (lane 3) mRNA
isolated from HMEC, amplified with primers specific for Col11a1;
(lane 4) mRNA isolated from human mammary cells, amplified
with Col11a1 primers; (lane 5) size of markers specified in #
basepairs.
Table 1 Reactivity of antisera for spliceforms of Collagen a1(XI)
Spliceform of Col11a1 Antisera
V1a C2 Npp V2 V1b
Col11a1p7 — X X — —
Col11a1p6a7 X X X — —
Col11a1p6b7 — X X — X
Col11a1p78 — X X X —
Col11a1p6a78 X X X X —
Col11a1p6b78 — X X X X
Col11a1p6a6b7 X X X — X
Col11a1p6a6b78 X X X X X
Antisera used for this study have overlapping and/or complementary
specificity as indicated by X. The eight potential spliceforms are listed
with an indication of which antisera will recognize the spliceforms.
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that normal human mammary epithelial cells ex-
press Col11a1 at the mRNA level (Figure 1).
Grossly normal and malignant human breast
tissue was obtained from pathology archives. Three
tissue microarrays containing 1 mm diameter cores
from 72 breast cancer cases were prepared using a
Quick-Ray arrayer (Woo-Ri Medic, Seattle, WA,
USA). Two tissue microarray blocks consisted of
nonmetastasized cases containing three cancer cores
and one normal core per case. The third tissue
microarray block consisted of cases with metastasis
and contained three cancer cores, two metastasis
cores, and one normal core per case. After comple-
tion, the blocks were incubated at 601C for 45 min,
embedded in paraffin, cut to 1mm thickness, and
heat fixed onto glass slides, as formerly described.33
To initiate deparaffinization, tissue microarray
slides were incubated for 25 min at 651C. Sequential
washes in xylene (twice for 5 min), absolute ethanol
(twice for 3 min), 95% ethanol (twice for 3 min), and
distilled water for 5 min were used for complete
deparaffinization and rehydration. Throughout the
subsequent staining process, the slides were stored
in a humidified slide moat (Boekel Scientific,
Feasterville, PA, USA) to prevent tissue desiccation.
A Pap pen (DakoCytomation, Dako North America
Inc., Carpinteria, CA, USA) was used to encircle the
tissue to contain the solution.
Hyaluronidase (H3506, Sigma-Aldrich Corpora-
tion, St Louis, MO, USA) was diluted to 0.01 mg/ml
in Tris buffer saline (TBS), pH 7.5 (0.2 M Tris-HCl,
0.17 M NaCl). This solution (200 ml) was placed on
each slide and incubated at 251C for 45 min.
Sequentially, TBS and distilled water were used to
rinse slides, which were subsequently placed into
95–991C Target Retrieval Solution, pH 7.5, (Dako-
Cytomation) for 40 min. The slides were permitted
to cool, followed by a 25 min incubation in Dual
Endogenous Enzyme Block for Autostainer (200 ml;
DakoCytomation) to quench endogenous peroxi-
dases. Slides were rinsed and immersed 3–5 times
in Wash Buffer (DakoCytomation).
Antibody diluent (DakoCytomation) was used to
dilute each primary antiserum to an optimal
concentration, which was determined by serial
dilutions prior to this study (V1a¼ 1:200;
C2¼ 1:200; Npp¼ 1:200; V2¼ 1:200; V1b¼ 1:25).
The tissue was incubated in 200 ml of primary
antiserum at 251C for 1 h. After incubation, slides
were rinsed, and 200 ml of an anti-rabbit and anti-
mouse secondary antibody, EnVisionþ Dual Link
System Peroxidase (DakoCytomation), was applied
to each slide and incubated for 30 min at 251C.
Following a wash step, each slide was covered with
200 ml of liquid DABþ Substrate Chromagen System
for Autostainer (DakoCytomation) and incubated for
20 min at 251C. After a distilled water rinse,
hematoxylin (7211, Richard-Allan Scientific,
Kalamazoo, MI, USA) was applied to each slide for
2 min at 251C; then the slides were rinsed
thoroughly and submerged in distilled water for
5 min. Dehydration of the tissue was accomplished
with consecutive ethanol-concentration steps and
xylene. A negative control excluding primary anti-
serum and a positive control using placenta tissue
were run with the tissue microarray slides for
quality control.34,32
The distribution of collagen a1(XI) in tissue
microarray cores was assessed by a pathologist
(JDK). Staining with five antisera against specific
regions of the NTD was evaluated to determine the
primary spliceforms present in breast tissue. For
three antisera, V1a, C2, and Npp, cores were
assessed to determine if epitopes were present in
cancer or normal and a score indicative of staining
intensity was given to cytoplasm, stroma, and
vasculature (intensity: 0¼no staining, 1¼weak
staining, 2¼ intermediate staining, 3¼ strong stain-
ing). Staining data were collected for the three
antisera with other tumor characteristics and case
demographics including: age, tumor size, overall
tumor grade (I, II, or III, as described in Elston and
Ellis8), nuclear polymorphism, tubule formation,
mitotic counts, angiolymphatic invasion, node sta-
tus, estrogen receptor status, progesterone receptor
status, and HER-2/neu status. If a case included
multiple cores of cancer or normal, the staining
intensities were averaged so that each case had only
one data point for cancer and one for normal.
SPSS 15 and the SAS package were used for
statistical analysis. The Pearson’s Product Moment
Correlation was used to determine correlation between
common pathologic parameters and lymph node
status. Repeated measures analysis of variance deter-
mined cytoplasm, stroma, and vascular staining out-
comes for each antiserum between cancer and normal
tissue. Finally, univariate analyses were carried out to
determine significance between staining of cancerous
breast tissue with the three antisera against collagen
a1(XI) and standard pathologic parameters.
Results
In this study, 72 cases of breast cancer were
evaluated. Of these, 18 women had lymph node
metastases. The average age of the patients was 63
years old (range: 34–90). Average tumor size of the
cases studied was 1.9 cm with 46 patients with
tumor size less than or equal to 2 cm and 25 patients
with tumor size greater than 2 cm. Of those, 15
patients had angiolymphatic invasion and 55 did
not. The study had 29 patients with an overall tumor
grade of I, 29 patients with an overall tumor grade of
II, and 10 patients with an overall tumor grade of III.
In addition, there were 8 patients with a tubule
formation score of 1, 18 with a tubule formation
score of 2, and 39 patients with a tubule formation
score of 3.
Typical clinical pathologic parameters
including tumor size, angiolymphatic invasion,
and tubule formation score correlated with node
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status (Table 2). The presence of angiolymphatic
invasion directly correlated with positive node
status (P¼ 0.037). Of the patients with axillary
lymph node metastases, 39% had angiolymphatic
invasion. Furthermore, of the patients without
metastasis, only 15% had angiolymphatic invasion.
With increasing tubule formation score and tumor
size, there was an increase in probability of
metastasis in the breast cancer cases assessed in
this study (P¼ 0.051, P¼ 0.037). Conversely, overall
tumor grade was not found to be a significant
predictor of lymph node metastasis in our study.
Collagen a1(XI) was variably expressed and
localized to epithelial cell cytoplasm, stroma, and
vascular structures within normal and cancerous
breast tissue. Col11a1 mRNA was detected in normal
human mammary epithelial cells by RT–PCR (Figure
1). Figure 2 illustrates the lack of staining with
antisera against the V1b and V2 regions of the NTD
when compared with the V1a antiserum used in this
study. Table 3 summarizes the significance of
staining in the regions with two antisera relative to
cancer vs normal tissue. Downregulation of collagen
a1(XI) in the stroma surrounding cancer epithelium
compared with normal tissue was evident with V1a
and Npp antisera (Figure 3; P¼ 0.0006, Po0.0001,
respectively). Antisera directed to the V1b and V2
regions of collagen a1(XI) did not detect any epitope
within the tissue analyzed. Table 4 reports the
statistically significant findings when staining in-
tensity in cancerous breast tissue was compared to
the standard pathological parameters, including
node status. There was an inverse relationship
observed between V1a antiserum cytoplasmic stain-
ing and node status; negative node status cases had
mean staining intensity of 2 and positive node status
cases had mean staining intensity of 1.5 (Figure 3;
P¼ 0.009). Stromal staining with Npp antiserum in
cancerous tissue demonstrated significance with
tubule formation score in an inverse manner with
more differentiated glandular tissue having more
staining (P¼ 0.015).
Collagen XI staining was also compared to
progesterone and estrogen receptor status for com-
parison (Figure 4). Cytoplasmic staining with Npp
antiserum exhibited significance and an inverse
relationship when assessed relative to positive
estrogen receptor status (P¼ 0.012) and to progester-
one status (P¼ 0.044).
Discussion
Collagen XI is a critical regulatory protein primarily
associated with fibril formation and limitation of
Figure 2 Staining with V1a (a), V2 (b), and V1b (c) antisera in breast cancer with adjacent normal tissue included within field.
Immunostaining: original magnification  100.
Table 2 Correlation of common pathologic parameters and node status in breast carcinomas analyzed by tissue microarrays
Parameter Number
of cases
Lymph node
positive (%)
Lymph node
negative (%)
Statistical
significance
Angiolymphatic invasion P¼ 0.037
Yes 15 7 (39) 8 (15)
No 55 11 (61) 44 (85)
Tubule formation score P¼ 0.051
1 8 1 (6) 7 (15)
2 18 2 (12) 16 (33)
3 39 14 (82) 25 (52)
Tumor size P¼ 0.037
r2 cm 46 8 (44) 38 (72)
42 cm 25 10 (56) 15 (28)
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fibril growth. It exists in several spliceforms, which
have not been studied previously in breast cancer.
The aim of this study was to determine if a
correlation exists between collagen a1(XI) and the
progression stage of breast cancer. Collagens have
been shown to change in neoplasms, and detection
of change in expression may lead to the develop-
ment of novel diagnostic and/or prognostic tools.
To confirm the validity of this study, known
predictors of node status in breast cancer patients
were evaluated. It was found that the presence of
angiolymphatic invasion correlated with positive
node status suggesting the two are directly related
and indicate poor prognosis. Previous studies
corroborated our results.2–7 Other pathologic clinical
parameters have been evaluated in earlier studies,
which suggest direct relationships between node
status and tubule formation score, tumor size, and
angiolymphatic invasion.3,5,6 Although overall tu-
mor grade was not found to be a significant predictor
of lymph node metastasis in our study, it has been
proven in earlier studies to have significance in
relation to node status.3,5–7 It is possible that
significance was not found due to small sample
size of 72 patients.
Cytoplasmic, stromal, and vascular staining was
observed with three Col11a1 antisera. Collagen XI is
an expected component of stroma. Current studies
are underway in our laboratory to understand the
cytoplasmic localization that has been observed in
some cases. It is possible that the NTD region once
cleaved from the major triple helix, may be involved
in other cellular processes or alternatively, may be
taken up by cells and targeted for degradation and
turnover. Alternatively, the data may indicate that
the protein accumulates within the cell rather than
being properly secreted. Previous studies have
identified a type V/XI hybrid molecule in cartilage
canals, perichondral invaginations of blood
vessels, and blood vessels (36 and unpublished
observations).
A relationship between the staining results of
cancer vs normal tissue demonstrated significance
with two antisera staining the stroma. Staining
intensity of stroma with V1a and Npp antisera was
significant relative to cancer vs normal, with stroma
surrounding normal epithelium consistently stain-
ing more intense than that surrounding cancerous
epithelium. This result is consistent with previous
findings that suggest modification in collagen
metabolism of cancerous breast tissue may be a
result of tissue remodeling in invasive malignan-
cies.24 On the contrary, various other cancers fail to
exhibit this same pattern of downregulation. Studies
of prostate cancer, lung cancer, and colorectal cancer
have reported upregulation of collagen in cancerous
tissue when compared with normal tissue.25–29
However, collagen XI was specifically considered
only in colon cancer and non-small-cell lung
cancer.25,29 Other collagens studied in relation to
cancer include collagen XVIII, a precursor to
angiogenesis inhibitor endostatin, which was shown
to indicate poor prognosis and progression of non-
small-cell lung cancer when overexpressed in the
malignancy.26 In addition, collagen XXIII, was
suggested as a biomarker of prostate cancer progres-
sion and metastasis.27 Increased collagen XXIII
expression in prostate cancer tissue was demon-
strated, and it was suggested that the amount of
expression is a significant independent predictor of
prostate-specific antigen defined disease recur-
rence.27 However, collagen expression in cancer
decreased with increased Gleason sum in a prostate
cancer study, which indicated that collagen content
in the cancer decreased whereas the collagen levels
in the adjacent normal tissue was dramatically
upregulated when compared with control normal
prostate from a patient without cancer.28 The
increased collagen content in surrounding tissue
was hypothesized to be due to a host response
against the tumor. Clinically, it was suggested to be a
predictor of patient survival.28
In prior breast cancer studies, collagen was
downregulated and in an earlier prostate cancer
study similar findings were demonstrated.24,28 These
findings support our results that collagen a1(XI)
Table 3 Staining intensity and location in normal vs cancerous tissue for the V1a and the Npp antisera to epitopes of Collagen a1(XI)
N-terminal domain
Antiserum and stain location Tissue type Mean of staining intensity Statistical significance
V1a cytoplasm Normal 2 NS
Cancer 2
V1a stroma Normal 0.5 P¼ 0.0006
Cancer 0
V1a vascular Normal 1.5 NS
Cancer 1
Npp cytoplasm Normal 1.5 NS
Cancer 1.5
Npp stroma Normal 1 Po0.0001
Cancer 0
Npp vascular Normal 1.0 NS
Cancer 1.0
Npp, amino propeptide; NS, nonsignificant.
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staining in stroma surrounding carcinoma is de-
creased as compared to stroma surrounding normal
epithelium.
Not only were staining results of cancer vs normal
tissue assessed, but we also looked at staining
intensity as a predictor of common pathologic
parameters including node status. Collagen a1(XI)
staining with V1a antiserum in epithelial cytoplasm
demonstrated decreased intensity in primary tumors
that had metastasized when compared with tumors
that did not metastasize. These results suggest a
downregulation of collagen a1(XI) in more advanced
tumors. This exhibits potential for further study that
may lead to developing collagen XI as a marker for
metastasis. The inverse relationship between inten-
sity of cytoplasmic staining in cancerous tissue with
V1a antiserum and tumor size may indicate that as a
tumor progresses the collagen XI content decreases.
Figure 3 Stromal staining with antiserum Npp in normal (a) and cancerous (b) human breast tissue. Cytoplasmic staining with V1a in
primary breast tumors of patients with nonmetastatic (c) and metastatic (d) disease. Immunostaining: original magnification 200.
Table 4 Statistically significant relationships between staining intensity and established pathologic parameters
Antiserum and stain location Parameter assessed Number of samples Mean stain intensity Statistical significance
Npp stroma in cancer Tubule formation score P¼ 0.015
1 8 0.5
2 15 0
3 39 0
Npp cytoplasm in cancer Progesterone receptor P¼ 0.044
Positive 28 1
Negative 40 1.5
Npp cytoplasm in cancer Estrogen receptor
Positive 35 1
P¼ 0.012
Negative 32 1.5
V1a cytoplasm in cancer Node status P¼ 0.009
Positive 17 1.5
Negative 52 2
Npp, amino propeptide.
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Because cytoplasmic staining with Npp antisera in
cancerous tissue demonstrated an inverse relation-
ship to positive estrogen receptor status and cyto-
plasmic staining with Npp antiserum exhibited
significance relative to progesterone status, it may
indicate that well-differentiated tumors with more
positive estrogen and progesterone receptors have a
relatively high expression of collagen XI. It appears
that as the tumor becomes less differentiated,
collagen XI expression declines. The lack of col-
lagen XI, a regulatory molecule, may contribute to
the uncontrolled growth of the tumor. Stromal
staining with Npp antiserum in cancerous tissue
demonstrated significance with tubule formation
score demonstrating a trend with well-differentiated
cancers of tubule formation score of 1 having more
staining than less differentiated tumors of tubule
formation score of 2 and 3. This inverse relationship
between differentiation and collagen XI expression
may indicate that collagen XI must be downregu-
lated for tumors to become less differentiated.
In the future, it would also be valuable to stain
normal breast tissue from patients without breast
cancer for comparison. In a previous study, normal
prostate from cancer-free patients was assessed in
addition to cancer and normal tissue from a patient
with prostate cancer.28 In addition, further study is
warranted to determine the mechanism underlying
downregulation of collagen XI in cancer when
compared with normal breast tissue. Because col-
lagen XI appears to be present in normal tissue at
higher levels, this suggests downregulation in
cancerous tissue as a desmoplastic response that
although significant statistically, its biological sig-
nificance is unknown. It may also be valuable to
look at collagen a1(XI) content of intraductal
carcinoma, the precursor to breast carcinoma, in
normal and cancer tissue.
In conclusion, collagen a1(XI) is expressed in
epithelial cells, stroma, and vessels of normal and
cancerous breast tissue. The spliceform containing
the region encoded by exon 6a, but excluding
regions encoded by exon 6b and exon 8 appears to
be the most prevalent form expressed in breast
tissue. Collagen a1(XI) stromal expression is mark-
edly decreased in breast carcinoma as compared to
patient matched normal tissue suggesting the possi-
bility of use as a future diagnostic tool. Additionally,
quantification of cytoplasmic and stromal expres-
sion of collagen XI may also be a valuable tool in
Figure 4 Estrogen and progesterone receptor staining for comparison. Estrogen receptor positivity in normal (a) and cancerous (b) human
breast tissue. Progesterone receptor positivity in normal (c) and cancerous (d) human breast tissue. Immunostaining: original
magnification 200.
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diagnosing lymph node status in patients providing
an alternative to invasive techniques such as
sentinel node biopsies. Further studies will be
necessary to validate our findings.
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